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Introduction
Although cartilage degeneration characterizes
human osteoarthritis (OA), changes also involve
the participation of the synovial membrane and the
subchondral bone.
In this review, attention will be focused on
current knowledge of the major factors participat-
ing in the degeneration of OA articular joints
tissues. Firstly, we will address the biochemical
agents involved in the destruction of cartilage and
synovial membrane. This will be followed by a brief
survey of the most important modulatory factors of
proinflammatory cytokines as well biological
agents as potential therapeutics. Emphasis will
then be placed on the possibility of an interaction
between subchondral bone and cartilage as an
integral part of the disease, leading and/or
contributing to cartilage destruction in OA; do
changes in one cause alterations in the other.
Pathophysiology of osteoarthritis
Osteoarthritis (OA) is an idiopathic disease
characterized by a degeneration of articular
cartilage. A breakdown of the cartilage matrix
leads to the development of fibrillation and
fissures, the appearance of gross ulcerations, and
the disappearance of the full thickness surface of
the joint. This is accompanied by bone changes
with osteophyte formation and thickening of the
subchondral plate. Moreover, at the clinical stage
of the disease, changes caused by OA involve not
only the cartilage but also the synovial membrane,
where an inflammatory reaction is often observed
[1].
A great deal of attention is focused on
identifying the protease responsible for the initial
occurrence of matrix digestion. Current knowledge
indicates an important involvement of matrix
metalloproteases (MMP). Of this family, members
from three groups in human articular tissues have
been identified as being elevated in OA, the
collagenases, the stromelysins and the gelatinases.
Another group of MMP, localized at the cell
membrane surface, has recently been discovered,
and named membrane type MMP (MT-MMP). Four
members have been identified. Although MT1-
MMP possesses properties of collagenase, and both
MT1-MMP and MT2-MMP are able to activate
gelatinase 72 kD and collagenase-3, the relevance
of these enzymes to OA has yet to be determined.
MMP biologic activity is controlled physio-
logically by specific tissue inhibitors of metallo-
proteases (TIMP) or by their activation. Enzymes
from the serine- and cysteine-dependent protease
families, such as the plasminogen activation/
plasmin system and cathepsin B respectively, have
been proposed as activators, and enhanced levels
of urokinase (uPA) and plasmin have been
identified in human OA cartilage [2]. Other
enzymes have also been found to act as MMP
activators. For example, stromelysin-1 activates
collagenase-1, collagenase-3 and gelatinase 92 kD;
collagenase-3 activates gelatinase 92 kD, MT-
MMP activates collagenase-3, and gelatinase
72 kD potentiates the latter activation; MT-MMP
also activates gelatinase 72 kD.
Current evidence suggests that proinflammatory
cytokines are responsible for the catabolic process
occurring in the pathological tissues. They appear
to be first produced by the synovial membrane, and
diffused into the cartilage through the synovial
fluid, where they activate the chondrocytes to
produce proinflammatory cytokines. In OA syn-
ovial membrane, it is the synovial lining cells that
play a major role as inflammatory effectors of
which interleukin (IL)-1b, Tumor necrosis factor
(TNF)-a, IL-6, leukemic inhibitor factor (LIF) and
IL-17 appear most relevant to the disease.
Osteoarthritis data strongly support the concept
that IL- 1b, and perhaps TNF-a, are the major
catabolic systems involved in the destruction of
joint tissues, and may constitute the in-situ source
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of articular tissue degradation. It is still unclear
whether IL-1b and TNF-a act independently or in
concert to induce the pathogenesis of OA, or if a
functional hierarchy exists between these
proinflammatory cytokines. In animal models, it
has been shown that blocking IL-1 or its activity is
very effective in preventing cartilage destruction
[3], whereas blocking TNF-a results in decreased
inflammation [4]. Both these cytokines have been
found in enhanced amounts in OA synovial
membrane, synovial fluid and cartilage.
IL-6 has also been proposed as a contributor to
the OA pathological process by: (1) increasing the
amount of inflammatory cells in synovial tissue; (2)
stimulating the proliferation of chondrocytes; and
(3) by inducing an amplification of the IL-1 effects
on the increased MMP synthesis and inhibition of
proteoglycan production. However, as IL-6 can
induce the production of tissue inhibitor of
metalloproteases (TIMP), and not MMP them-
selves, it is believed that this cytokine is involved
in the feedback mechanism that limits enzyme
damage.
LIF is another cytokine of the IL-6 family that is
upregulated in OA synovial membrane and fluid,
and produced by chondrocytes in response to the
proinflammatory cytokines, IL-1b and TNF-a [5].
This cytokine stimulates cartilage proteoglycan
resorption, as well as MMP synthesis and nitric
oxide (NO) cellular production [6]. However, its
role in OA has not yet been clearly defined.
IL-17 is a newly discovered cytokine of 20–30 kD
present as a homodimer and with variable
glycosylated polypeptides. The nature of the tissue
distribution of IL-17 receptor (R) appears ubiqui-
tous. IL-17 upregulates a number of gene products
involved in cell activation including the proinflam-
matory cytokines, IL-1b, TNF-a and IL-6, as well as
MMP, in target cells such as human macrophages
[7]. IL-17 also increases the production of NO in
chondrocytes [8]. The role of LIF, in OA remains
undetermined.
In addition, the inorganic free radical NO has
been suggested as a factor that promotes cartilage
catabolism in OA. Compared to normal, OA
cartilage produces a larger amount of NO, both
under spontaneous and proinflammatory cytokine-
stimulated conditions [9] resulting in an enhanced
expression and protein synthesis of the inducible
NO synthase (iNOS). A high level of nitrite/nitrate
has been found in the synovial fluid and serum of
arthritic patients.
In the inflammatory response of OA articular
cells, the changes in cyclooxygenase-2 (COX-2)
expression and/or activity seem one of the major
determinants for prostaglandin (PG)E2 production.
While the induction of COX-2 and iNOS appear to
be separate processes, interaction in some target
cells between these two systems was recently
reported [10]; the NO stimulation of IL-1b and
TNF-a-induced COX-2 expression was suggested to
be mediated by cyclic quanosine monophosphate
(cGMP). However, in an in-vitro study on chondro-
cytes, it was shown that inhibition of NO
production enhanced PGE2 production [11].
Natural inhibitors capable of directly counter-
acting the binding of the cytokine to cells or
reducing the proinflammatory level have been
identified, and can be divided into three categories
based on their mode of action. The first inhibitor
category is a receptor-binding antagonist of which
to date only the IL-1 receptor antagonist has been
found. The second category is the soluble receptors
for IL-1b and TNF-a that are truncated forms of the
receptors. Other natural inhibitors able to reduce
proinflammatory cytokine production and/or ac-
tivity are the cytokines having anti-inflammatory
properties. Four such cytokines, namely transform-
ing growth factor (TGF)-b, IL-4, IL-10 and IL-13,
have been identified as able to modulate various
inflammatory processes including a decreased
production of proinflammatory cytokines such as
IL-1b and TNF-a, as well as some proteases, and an
upregulation of IL-1Ra and TIMP production.
Current therapeutic strategies of antagonizing
IL-1b and TNF-a with either receptor blockade
(with IL-1Ra) or molecular quenching (with IL-1R
or TNF- R soluble receptors) have proven valuable
in other arthritic diseases and in animal models of
OA. Moreover, in-vivo therapeutic effects of a
selective inhibitor of iNOS on the progression of
lesions in experimental arthritis and OA [12]
models have recently been reported.
In addition to degeneration of the articular
cartilage, OA involves changes in the surrounding
bone. The recently expanded body of knowledge
concerning the subchondral bone provides the
basis upon which we may assert that this tissue is
intimately involved in the pathology of OA. It is
suggested that thickening of the subchondral bone
may participate in the progression of OA. Whether
bone sclerosis initiates or is involved in the
progression of cartilage loss remains a matter of
debate.
Opposing concepts can explain a stiffening of the
subchondral bone. In subchondral bone, the
healing of trabecular microfractures, which are
present due to repetitive impulsive loading of the
joint and remodeling of the bony internal
architecture to better resist these stresses, can
generate a stiffer bone that is no longer an
effective shock absorber [13, 14]. Conversely,
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subchondral bone stiffness may be part of a more
generalized bone alteration leading to increased
bone mineral density/volume.
The hypothesis that abnormal OA osteoblasts
directly influence cartilage metabolism has re-
cently been put forward [15, 16]. In one study [15]
it was shown that conditioned media from primary
osteoblasts of OA patients versus subjects without
arthritis significantly altered glycosaminoglycan
release from normal cartilage in vitro, while
cytokine release from these cells remained intact.
Recently, Hilal et al. [16] reported that in vitro
primary cultures of osteoblasts from human OA
subchondral bone have an altered phenotype, and
that the plasminogen activator (urokinase)/plas-
min system activity and IGF-1 levels are elevated
in these cells, explaining the above observations.
Although cartilage degeneration characterizes
human OA, alterations of this disease also involve
the participation of the synovial membrane and
subchondral bone. Both clinical and laboratory
evidence indicate an altered subchondral bone
metabolism in OA, possibly due to abnormal
osteoblast behavior. Coupled with mechanical/
chemical stresses, abnormal OA osteoblasts would
then accelerate subchondral bone formation,
which would enhance the mechanical pressure on
the overlying cartilage in supporting joints,
promoting further deterioration and cartilage
erosion. The role for a local factor(s) produced by
osteoblasts (including PA/plasmin and IGF sys-
tems) promoting cartilage breakdown and/or
increasing subchondral bone turnover is gaining
support.
The current understanding of the factors
involved in this disease has evolved greatly during
recent years. A better comprehension of the
modulating factors as well as the major regulators
has and will continue to generate new insights into
a more accurate identification of effective targets
having therapeutic potential in the treatment of
OA. The future holds great promise for the
development of new and successful approaches to
the treatment of this disease.
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